Real-world effectiveness of CDK4/6 inhibitors in older patients with HR+/HER2- advanced breast cancer: a sub-analysis of the multicenter, PALMARES-2 study
Rattachement africain : it, us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: Older patients with Hormone Receptor-positive, HER2-negative advanced breast cancer (HR+/HER2- aBC) are often frailer than younger patients. Endocrine therapy (ET) plus CDK4/6 inhibitors (CDK4/6i) is the standard first-line treatment regardless of age; however, CDK4/6i real-world effectiveness in older patients is unknown. PATIENTS AND METHODS: PALMARES-2 (NCT06805812) is a large real-world study investigating first-line ET plus CDK4/6i effectiveness in HR+/HER2- aBC patients. We compared real-world progression-free survival (rwPFS) between older (>75 years) and younger (≤75 years) patients in the whole study cohort, as well as in palbociclib, ribociclib, or abemaciclib sub-cohorts. Cox regression models and inverse probability of treatment weighting (IPTW) were used to adjust for prognostic covariates. RESULTS: Older patients accounted for 302 (15.2%) of the PALMARES-2 study cohort (n = 1982). Compared with younger patients, older patients were less likely to have ECOG PS 0 or bone-only disease, and more likely to receive palbociclib. At multivariable analysis, older patients had better rwPFS when compared to younger patients (aHR 0.77; 95% CI 0.67-0.90, p = 0.001). In younger patients, ribociclib and abemaciclib were more effective than palbociclib, whereas in older patients palbociclib showed similar effectiveness to abemaciclib and superior effectiveness to ribociclib (p for interaction <0.001). Among patients treated with palbociclib, older patients had improved rwPFS compared with younger patients (aHR 0.69; 95% CI 0.57-0.84, p < 0.001). CONCLUSION: First-line ET plus CDK4/6i is highly effective in older patients with HR+/HER2- aBC. Based on effectiveness and clinical manageability, palbociclib represents a particularly suitable option in this population.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Real-world effectiveness of CDK4/6 inhibitors in older patients with HR+/HER2- advanced breast cancer: a sub-analysis of the multicenter, PALMARES-2 study
- Date Crossref
- 01/06/2026
- Éditeur
- Elsevier BV
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Fondazione IRCCS Istituto Nazionale dei Tumori pays non établi dans la noticeÉtablissement de santé
-
Istituto Oncologico Veneto pays non établi dans la noticeÉtablissement de santé
-
European Institute of Oncology Division of Medical Senology pays non établi dans la noticeÉtablissement de santé
-
Federico II University Hospital pays non établi dans la noticeÉtablissement de santé
-
University of Naples Federico II pays non établi dans la noticeUniversité ou école supérieure
-
Sapienza University of Rome Department of Radiological pays non établi dans la noticeUniversité ou école supérieure
-
Ospedale Policlinico San Martino pays non établi dans la noticeÉtablissement de santé
-
Policlinico San Matteo Fondazione pays non établi dans la noticeÉtablissement de santé
-
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia pays non établi dans la noticeÉtablissement de santé
-
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori pays non établi dans la noticeStructure de recherche
-
ASST Fatebenefratelli Sacco pays non établi dans la noticeÉtablissement de santé
-
Università degli Studi del Piemonte Orientale “Amedeo Avogadro” pays non établi dans la noticeUniversité ou école supérieure
Fondazione IRCCS Istituto Nazionale dei Tumori, Istituto Oncologico Veneto et Division of Medical Senology — European Institute of Oncology, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.